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Objective: To provide a detailed phenotype/genotype characterization of Bietti Crystalline Dystrophy (BCD). 48 
Design: Observational case series.  49 
Participants: Twenty patients from 17 families recruited from a multi-ethnic British population.  50 
Methods: Patients underwent color fundus photography, near infra-red (NIR) imaging, fundus 51 
autofluorescence (AF) imaging, spectral domain-optical coherence tomography (SD-OCT) and 52 
electroretinogram (ERG) assessment. The gene CYP4V2 was sequenced.  53 
Main Outcome Measures: Clinical, imaging, electrophysiological and molecular genetics findings.  54 
Results: Patients ranged in age from 19 to 72 years (median 40), with visual acuity of 6/5 to perception of 55 
light (median 6/12). There was wide intra- and inter-familial variability in clinical severity. Fundus AF 56 
imaging showed well defined areas of retinal pigment epithelium (RPE) loss which corresponded on SD-OCT 57 
to well demarcated areas of outer retinal atrophy.  Retinal crystals were not evident on fundus AF imaging, 58 
and were best visualized with NIR imaging. SD-OCT showed them to be principally located on or in the 59 
RPE/Bruch’s membrane complex. Disappearance of the crystals, revealed by serial recording, was 60 
associated with severe disruption and thinning of the RPE/Bruch’s membrane complex. Cases with 61 
extensive RPE degeneration (N=5) had ERGs consistent with generalized rod and cone dysfunction, but 62 
those with more focal RPE atrophy either showed amplitude reduction without delay (N=3), consistent with 63 
restricted loss of function, or were normal (N=2). Likely disease-causing variants were identified in 34 64 
chromosomes from 17 families. Seven were novel including p.Met66Arg, found in all 11 patients from 8 65 
families of South Asian descent. This mutation appears to be associated with earlier onset (median age 30) 66 
compared to other substitutions (median age 41). Deletions of exon 7 were associated with more severe 67 
disease. 68 
Conclusions: The phenotype is highly variable. Several novel variants are reported, including a highly 69 
prevalent substitution in patients of South Asian descent associated with earlier onset disease. AF showed 70 
sharply demarcated areas of RPE loss which coincided with abrupt edges of outer retinal atrophy on SD-71 
OCT; crystals were generally situated on or in the RPE/Bruch’s complex but could disappear over time with 72 





Bietti crystalline corneoretinal dystrophy (BCD, Online Mendelian Inheritance in Man (OMIM) 210370) is a 76 
rare autosomal recessive disease that is characterized by yellow-white crystalline retinal deposits, 77 
progressive atrophy of the retinal pigment epithelium (RPE) and loss of choriocapillaris. In some patients, 78 
but not all, this is accompanied by crystalline deposits at the corneal limbus.1 BCD typically presents 79 
between the second and fourth decade with progressive night blindness, reduced vision and visual field 80 
constriction, often with legal blindness in the fifth or sixth decades of life.1 In 2000 Jiao et al mapped BCD to 81 
chromosome 4q35.12 and subsequently Li and colleagues identified disease-causing variants in CYP4V2, a 82 
novel member of the cytochrome P450 gene family (family 4, subfamily V, polypeptide 2).3 83 
The majority of phenotypic data are derived from a small number of case reports and case series, with the 84 
largest series to date describing 21 patients.4-9 The main characteristics and natural history of the disease 85 
are reasonably well characterized, but there remain areas of uncertainty, including the precise intraretinal 86 
location of the crystals and primary pathology, the degree of variability and its association, if any, with the 87 
underlying mutations, the pattern of cell loss and its retinal distribution. There is limited information on the 88 
time course of crystal formation within the retina and few studies have described the retinal characteristics 89 
using newer imaging modalities such as near infra-red (NIR) imaging and spectral domain optical coherence 90 
tomography (SD-OCT). 91 
This report describes the detailed clinical features and molecular pathology in a cohort of 20 patients from 92 
17 families affected by BCD from a British multi-ethnic population, and examines the relationship between 93 
disease-causing variants and disease severity.  94 
 95 
Methods 96 
Twenty patients with a clinical diagnosis of BCD were ascertained from Moorfields Eye Hospital, London, 97 
United Kingdom over a 13-year period from 1999 to 2012. Patients were recruited from one of three 98 
ophthalmologists’ clinics (ARW, ATM, MM) and included in the study only if all clinical data were consistent 99 
with the diagnosis. This was later confirmed with CYP4V2 sequencing. Patients provided informed consent 100 
as part of a research project approved by the local research ethics committee, and all investigations were 101 
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conducted in accordance with the principles of the Declaration of Helsinki. One patient (case 19) has been 102 
described previously.6 103 
Clinical studies: 104 
All patients had their clinical history documented and underwent eye examinations which included best-105 
corrected visual acuity, slit lamp biomicroscopy, dilated fundus examination and digital fundus photography 106 
(TRC-501A; Topcon, Tokyo, Japan). The severity of fundus appearance was graded according to the scale 107 
proposed by Yuzawa et al.10 and simplified by Weleber and Wilson11 which describes 3 stages of increasing 108 
severity – stage 1: RPE atrophy only; stage 2: RPE and choroidal atrophy localized to the macular region; 109 
stage 3: RPE and choroidal atrophy extending beyond the macula. Severity grading was performed by one 110 
investigator (GL) and independently checked by another (AGR). Disagreements were adjudicated through 111 
discussion and the consensus grading was used. Imaging studies were addressed in a similar fashion. 112 
Imaging: 113 
The Spectralis HRA + OCT with viewing module version 5.1.2.0 (Heidelberg Engineering, Heidelberg, 114 
Germany) was used to acquire autofluorescence (AF) images over 30x30: and 55x55: fields as well as SD-115 
OCT images. Fundus autofluorescence imaging (FAF) was available in 17 patients; SD-OCT in fifteen 116 
patients; 11 patients had longitudinal data available. The SD-OCT protocol included a dense horizontal 117 
linear scan centered on the fovea and the HEYEX software interface (version 1.6.2.0; Heidelberg 118 
Engineering) was used to correlate position markers on NIR and SD-OCT scanning to localize lesions. The 119 
same program also allows registration of blood vessels from the NIR images to facilitate longitudinal 120 
analysis of crystal evolution. The location of crystals was correlated across color photographs, NIR, AF and 121 
SD-OCT imaging using side-by-side comparisons, and where available, HEYEX position markers. 122 
Observations had to be replicated in at least two patients before they were accepted as valid and described 123 
in this study.  124 
Electrophysiology: 125 
Eleven patients underwent electrophysiological assessment using full field electroretinography (ERG) and 126 
pattern ERG. All protocols incorporated the recommendations of the International Society for Clinical 127 
Electrophysiology of Vision (ISCEV) standards.12-14 128 
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CYP4V2 mutation screening 129 
Blood samples were collected and DNA was extracted using the Puregene blood extraction kit (Invitrogen, 130 
Paisley, UK) following manufacturer’s instructions. Each of the 11 exons of CYP4V2 was amplified from 131 
patient genomic DNA using primers located in the flanking intron and untranslated regions. The primers 132 
and conditions were as described previously3 and allowed each exon, including splice junctions to be 133 
amplified.  134 
The products were purified using Qiagen polymerase chain reaction (PCR) purification columns (Qiagen, UK) 135 
and sequenced using the fluorescently-labeled dideoxy-terminator method on an ABI 3100 Automated DNA 136 
Sequencer (Applied Biosystems, UK). Electropherograms were analyzed for sequence changes using 137 
DNAStar computational software (DNAStar, Inc., USA). Sequencing data obtained from PCR products were 138 
analyzed using SeqMan, a program designed to detect potential alterations in the sequence. Any sequence 139 
changes identified were checked visually. When family samples were available the segregation of 140 
potentially disease-causing variants was investigated. Missense mutations were analyzed using three 141 
software prediction programs: 142 
SIFT (Sorting Intolerant from Tolerance) (J. Craig Venter Institute; Available at: http://sift.jcvi.org/. Accessed 143 
August 1, 2013.), PolyPhen2 (Available at: http://genetics.bwh.harvard.edu/pph/index.html. Accessed 144 
August 1, 2013) and pMUT (University of Barcelona Molecular Recognition & Bioinformatics Group; 145 
Available at: http://mmb.pcb.ub.es/PMut/. August 1, 2013) splice mutations were analysed using 146 
NetGene2 (Technical University of Denmark Center for Biological Sequence Analysis; Available at: 147 
http://www.cbs.dtu.dk/services/NetGene2/ Accessed October 15, 2013). 148 
Fluorescence in situ hybridization (FISH) 149 
Chromosome slides for FISH analysis were obtained from peripheral blood lymphocyte cultures following 150 
standard cytogenetic procedures. Prior to the hybridization the slides were denatured in 70% formamide at 151 
70oC for 2 minutes, quenched in 2xSSC at 4oC and then dehydrated in an ethanol series. The FITC-labeled 152 
BAC probe 173M11 (Empire Genomics) was co-hybridized to the slides with a TRITC-labeled chromosome 4 153 
specific “paint” (Cambio). Hybridization and post-hybridization washes were carried out following the 154 
manufacturers’ instructions. The slides were mounted with Vectashield (Vector Laboratories) containing 4', 155 
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6-diamidino-2-phenylindole (DAPI) for chromosome counterstaining. Image capture and analysis were 156 
carried out on a CytoVysion system (Genetix) consisting of an Olympus BX-51 epifluorescence microscope 157 
coupled to a JAI CVM4+ CCD camera. At least 30 informative metaphases per sample were captured and 158 
analyzed. 159 
Comparative genomic hybridization (CGH) 160 
Array CGH was used to evaluate DNA copy number differences on chromosome 4 (performed by 161 
NimbleGen Systems Inc). Test samples (patients 3 and 7) were labeled with Cy-3 and the reference sample 162 
was labeled with Cy-5. The data were visualized using SignalMap software (NimbleGen). The array was 163 
designed, and labeling, hybridization and normalization were performed at NimbleGen. Subsequent 164 
analysis was performed in-house. 165 
Long range PCR 166 
Potential breakpoints for a CNV of interest 5’ of CYP4V2 were identified by visual inspection of array CGH 167 
data. Primers were designed approximately 2kb 5’ and 500bp 3’ of the maximal predicted CNV region, with 168 
the following sequences: CYP4V2 F2 5’-CAAGGACTCATCCTGATCAC-3’ and CYP4V2 R1 5’-169 
AGCCTAGTGAGCTTGTCACA-3’. Long range PCR was performed using the Bio-X-Act Long kit (Bioline) 170 
following manufacturer’s protocols, with >10ng template DNA, 1.5mM Mg2+ and cycling conditions of 95oC 171 
2 minutes, 60oC 1 minute, followed by 35 cycles of 95oC 30 seconds, 60oC 30 seconds and 68oC 20 minutes, 172 
with a final extension step of 68oC for 20 minutes. 173 
Quantitative PCR (qPCR) 174 
Nine pairs of primers were designed at regular intervals across the CYP4V2 region, from approximately 175 
25kb 5’ of the gene to approximately 15kb 3’, using Primer3 (http://frodo.wi.mit.edu/. Accessed March 13, 176 
2012), sequences and PCR conditions are given in Table 1 (available at http://aaojournal.org). Quantitative 177 
PCR (qPCR) was performed using QuantiFast (Qiagen) following manufacturer’s protocols. Reactions were 178 
performed on a Step One Plus real time PCR system (Applied Biosystems) in 25µl total volume, using 10ng 179 
diluted DNA as template and with final concentrations of 1µM of each primer. PCR efficiencies were 180 
determined using serial dilutions of a control DNA sample. Data was analyzed in Microsoft Excel using the 181 
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Comparative CT Method (ΔΔCt), normalizing against the 5’ most primer pair, and a pair located in TMEM107 182 
(chr17:8,076,297-8,079,714). 183 
Statistical analyses 184 
Kaplan Meier survival analysis was used to compare the age of onset of symptoms for different mutations. 185 
Median survival time to onset of symptoms was derived from the Kaplan Meier product limit estimators. 186 
Visual acuity was converted from Snellen acuity into LogMAR units (Logarithm of the Minimum Angle of 187 
Resolution) and analyzed as the algebraic mean of two eyes, the better seeing eye, and the worse seeing 188 
eye. LogMAR was grouped into 4 categories as <0.3, 0.3≤LogMAR<0.5, 0.5≤LogMAR<1 and ≥1 and analyzed 189 
as an ordinal variable. Severity of disease and electrophysiological abnormalities (no, mild and severe 190 
generalized retinal dysfunction) were also analyzed as ordinal variables using Fisher’s exact test (univariate 191 
analyses) and ordinal logistic regression (adjusting for age and gender). Additional patient data was 192 
extracted from a publication by Lai et al.15 and used for pooled analyses. SAS version 9.2 (SAS Institute, Cary 193 
NC) was used for analyses.  194 
Results 195 
Clinical presentation 196 
The clinical phenotypes are summarized in Table 2 (available at http://aaojournal.org). There was marked 197 
intra- and inter-familial variability. The 20 patients, 10 male and 10 female, ranged in age from 19 to 72 198 
years (median 40 years). Visual acuity varied from 6/5 to perception of light (median 0.3 logMAR, 6/12). 199 
The onset of symptoms varied from 22 -45 years, with most patients (n=15, 75%) presenting in the third or 200 
fourth decade of life with reduced central vision (n=12) and/or nyctalopia (n=6); 2 patients were 201 
asymptomatic at the time of presentation and detected through presentation for unrelated conditions (e.g. 202 
corneal foreign body). Visual acuity was highly variable and was not age-related (Table 2, available at 203 
http://aaojournal.org). For example, patient 13 had 6/6 vision in both eyes aged 40 years, whereas patient 204 
6 had only perception of light vision in both eyes at a similar age. Five patients (25%) had moderate myopia 205 
(-3 to -5 dioptres) while the others were emmetropic or had low myopia. Family GC19455 showed a 206 
pseudodominant mode of inheritance with an affected father and two affected sons from a 207 
consanguineous family. All other patients were simplex cases, with 1 pair of affected dizygotic twins 208 
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(patients 1 and 2, GC5048), and an affected sibling of patient 8 (not included in this study as not a patient of 209 
this center). A sample of pedigrees is provided in Figure 1 (available at http://aaojournal.org). 210 
On clinical examination all patients had retinal crystals at the posterior pole with varying degrees of RPE 211 
and inner choroidal atrophy. Four patients from different families (20%) had crystalline deposits at the 212 
corneal limbus, and all had either stage 2 or 3 disease. Patients 1 and 2 (GC5048) were dizygotic twin sisters 213 
from a non-consanguineous pedigree with a somewhat discordant phenotype; patient 1 had an earlier 214 
onset of disease (age 29), vision of 6/60 in both eyes, stage 3 disease and undetectable PERGs in keeping 215 
with severe macular dysfunction and ERG evidence of generalized rod and cone photoreceptor dysfunction. 216 
Her sibling had onset of symptoms 4 years later (age 33), vision of 6/12 in both eyes, a similar appearance 217 
of sparse retinal crystals and widespread atrophy (stage 3) but with less severe macular and generalized 218 
retinal dysfunction than her sister (Table 2, available at http://aaojournal.org). In GC19455 both the older 219 
son (proband, patient 13) and father (patient 12) had stage 1 disease localized to the macula, while the 220 
younger son (patient 14) had stage 3 disease with a much greater extent of involvement despite being the 221 
youngest affected in the pedigree. However, in general, older patients had fewer crystals and more severe 222 
retinal atrophy. 223 
Retinal Imaging 224 
Color, AF and SD-OCT scanning of patients with different presentations is shown in Figure 2. Areas of RPE 225 
and choroidal atrophy tend to develop at the posterior pole, become confluent and expand centrifugally to 226 
involve peripheral retina. Areas of normal looking retina anterior to the macula showed normal AF (Figure 227 
2B), while involved areas showed abnormal AF which progressed to become sharply demarcated areas of 228 
hypo-AF (Figures 2E, 2K, 2N). These sharply demarcated areas correspond to relatively abrupt loss of outer 229 
retinal layers including the outer plexiform and outer nuclear layers on SD-OCT (Figure 2F, 2L).  230 
Crystals seen on color photographs were not visualized on FAF but were highly reflective on NIR imaging 231 
(Figures 3A-C; 3E-G). SD-OCT scans revealed hyperreflective spots located in or on the RPE/Bruch’s 232 
membrane complex (Figure 3D, 3H up arrows) corresponding to these crystals on color and NIR images. 233 
The majority of crystals in all patients were located in or on the RPE/Bruch’s membrane complex. However, 234 
not all hyperreflective lesions seen on SD-OCT spatially associated with crystalline deposits, as shown in 235 
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Figure 3H (down arrow), where the hyperreflective spot in the inner plexiform layer did not correspond to a 236 
crystal on either color or NIR images. Outer retinal tubulations were observed in all patients, except patient 237 
19, who was also the youngest patient (19 years) in the case series. There were no hyperreflective spots 238 
suggestive of crystals in the choroid in any patient.  239 
The appearance of a new crystal in the RPE/Bruch’s membrane layer of patient 11 in 2012 which was not 240 
present in corresponding scans in 2010 is shown in Figure 4. The overlying external limiting membrane 241 
remained intact above the new crystal. Crystal disappearance was associated with thinning of the 242 
RPE/Bruch’s membrane layer, loss of the ellipsoid and external limiting membrane layers, and the 243 
formation of what is likely to be an early retinal tubulation. 244 
Electrophysiology 245 
Electrophysiology was performed on 11 patients and revealed a range of abnormalities (Table 2 and Figure 246 
5, both available at http://aaojournal.org). The ERGs in five of 5 patients with extensive RPE/choroidal 247 
atrophy (patients 1, 2, 6, 11 and 17) showed evidence of generalized rod and cone photoreceptor 248 
dysfunction whereas 3 patients with atrophic lesions confined to the maculae (patients 3, 5 and 10) showed 249 
restricted loss of cone and/or rod system function (ERG amplitude reduction without delay). Two further 250 
patients with focal macular atrophy had normal full-field ERGs (patients 7 and 13). One patient without 251 
atrophy had normal ERGs (patient 19).  252 
The pattern ERG P50 component, reflecting macular function, was subnormal bilaterally in 9 patients (1-3, 253 
6, 7, 10, 11, 13 & 17); unilaterally in 1 (patient 5). Six of 10 patients showed significant P50 component 254 
delay bilaterally (patients 2, 3, 5, 6, 10 and 17). There was no clear correlation between the 255 
electrophysiological abnormality and age although the youngest patient with macular crystals without 256 
atrophy had normal pattern and full-field ERGs (patient 19; age 15 years).  257 
Molecular analysis 258 
Twenty patients from 17 families were screened. Likely disease-causing variants were found in all 34 259 
chromosomes from the 17 families and comprised 11 distinct variants in CYP4V2 (Table 2, available at 260 
http://aaojournal.org, and Table 3). The majority (7/11) of the variants were missense mutations. 261 
Interestingly, the most common mutation in our cohort was a novel variant c.197T>G (p.Met66Arg) which 262 
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was seen in 16/34 chromosomes (47%). This variant was identified in a homozygous state in all 11 patients 263 
in 8 families of South Asian ancestry (Table 2, available at http://aaojournal.org), but not in other patients 264 
of European, East Asian or Middle Eastern ancestry. Seven further missense mutations were also identified, 265 
4 (6/34 chromosomes, 18%) were novel and 3 have been previously described (4/34 chromosomes, 12%). 266 
The next most common mutation detected in our cohort was an indel spanning a splice acceptor site, 267 
previously shown to cause the in-frame deletion of exon 73 and this occurred in 6/34 (18%) chromosomes. 268 
One instance each of two potential novel splice site mutations and one nonsense mutation completed the 269 
spectrum of mutations. The mutations published to date, including the novel variants reported in this 270 
study, are represented schematically in Figure 6 (available at http://aaojournal.org) and suggests that there 271 
is no significant clustering of the variants, which have been found throughout the entire coding sequence of 272 
the gene.  273 
In silico analysis of these missense variants using three methods, SIFT, Polyphen 2 and pMUT, showed that 274 
they are all predicted to be disease-causing by all three methods with the exception of p.Gly26Asp and 275 
p.Met66Arg. The p.Gly26Asp change is only reported by Polyphen 2 to be probably damaging, whereas SIFT 276 
and pMUT predict it is a tolerated change (Table 3). This substitution was only seen in one patient who also 277 
had a putative splice-site mutation, c.985+3A>G in intron 7. Analysis of this potential splicing mutation 278 
using NetGene2 showed that the donor splice site at the 3’ end of exon 7 is abolished when the A at 279 
position +3 is changed to a G. This would result in an mRNA that does not splice to exon 8 but adds on 10 280 
amino acids before a stop codon truncates it. This patient (patient 5) had relatively mild disease given her 281 
age (stage 2, mild full field ERG abnormalities, 55 years) but otherwise had typical BCD with corneal and 282 
retinal crystals (Table 2, available at http://aaojournal.org). The p.Met66Arg substitution which is reported 283 
for the first time here is predicted by Polyphen 2 to be benign but SIFT and pMUT both predict it to be a 284 
pathological change with good reliability in pMUT. The other predicted splice mutation, c.327+11G>C needs 285 
further analysis.  286 
Fifteen of the 17 families harbored homozygous mutations. Multiple single nucleotide polymorphisms 287 
(SNPs) were also detected (Table 4). The most common mutation (16/34 chromosomes) in the present 288 
cohort was the novel missense mutation p.Met66Arg. This was identified in the homozygous state in all 8 289 
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families of South Asian descent. Analysis of 11 SNPs across CYP4V2 (shown in Table 3 but excluding 290 
rs35200327) showed that there is an associated haplotype (G-C-C-G-A-C-G-G-C-A-G). This haplotype also 291 
occurs in a homozygous state in these patients suggesting a founder effect.  292 
Examining copy number variation (CNV) of CYP4V2 293 
The finding that the majority of our patients had homozygous mutations and were not reported as being 294 
from consanguineous families raised the possibility that there may be a common deletion in this region of 295 
chromosome 4, making the individuals appear homozygous, when they are really hemizygous for the 296 
reported variant. To test this hypothesis, patient 4, a Turkish woman diagnosed in her early 20’s, was 297 
initially examined. Metaphase spreads were prepared from peripheral blood lymphocytes and a 298 
fluorescently labeled probe from a PAC clone (173M11) containing CYP4V2 and a chromosome 4 paint were 299 
used to examine the region. This fluorescent in situ hybridization (FISH) showed that patient 4 has two 300 
copies of the gene (Figure 7a, available at http://aaojournal.org). Subsequently samples were obtained 301 
from the family (GC17557) and analysis showed each parent had one wild type CYP4V2 and one mutated 302 
copy (c.677T>A, p.Met226Lys), and that her 2 siblings harbored two wild type copies (Figure 7b, available at 303 
http://aaojournal.org). Patient 8 was used as a control as he was a compound heterozygote and FISH 304 
confirmed he also had 2 copies of the gene as expected (data not shown). Analysis of this family (GC4795) 305 
demonstrated that his father was a carrier of a missense mutation (c.1503G>A, p.Arg400His) and his 306 
mother a carrier of the splice mutation c.802-8_810del17insGC (Figure 1, available at 307 
http://aaojournal.org).  308 
In order to determine whether other members of the cohort exhibiting apparent homozygosity across the 309 
gene might instead have a CNV, DNA was sent for array comparative genomic hybridization (aCGH) analysis. 310 
DNA from patients 3 and 7 (European and of South Asian descent respectively) were analyzed using a 311 
custom array designed to cover this region of chromosome 4. Probes were 20bp apart for the region of 312 
interest on chromosome 4 and 250bp apart for the rest of chromosome 4. Nimblegen analysis indicated a 313 
deletion in patient 7 and a duplication in patient 3, spanning ~4.8kb in the region chr4:187,093,500-314 
187,098,300 (Hg19), approximately 15kb 5’ of CYP4V2 (Figure 8, available at http://aaojournal.org). This is a 315 
region of known copy number variability (Database of Genomic Variants; http://projects.tcag.ca/variation/. 316 
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Accessed March 12, 2012), and is mainly non-genic, with the exception of ~300bp of the 3’ untranslated 317 
region on FAM149A, the gene immediately flanking CYP4V2 upstream. To further explore the role of CNVs 318 
in CYP4V2, qPCR analysis of the region spanning chr4:187,088,471-187,149,502 (from ~25kb 5’ of CYP4V2 319 
to ~15kb 3’) was performed on three patients (patients 3, 5, and 7). The placement of the primers was 320 
designed to detect CNVs within CYP4V2, rather than in the potential 5’ CNV indicated by the Nimblegen 321 
data. The results provided no convincing evidence of CNVs in CYP4V2 in any of these three patients (data 322 
not shown). These data support the assertion that these probands were homozygotes rather than 323 
hemizygotes for mutations in CYP4V2. 324 
Genotype-phenotype correlations 325 
The patients displayed wide phenotypic variability; the oldest patient (patient 12, 72 years, homozygous 326 
p.Met66Arg) had one of the mildest phenotypes (stage 1), while one of the younger patients (patient 6, 39 327 
years, heterozygous deletion exon 7) had one of most severe phenotypes (stage 3).  328 
Mutations were grouped into 3 categories, those homozygous for p.Met66Arg (n=11), homozygous or 329 
heterozygous for other substitutions (n=5) and homozygous or heterozygous for deletion of exon 7 (n=4) 330 
and tested for associations with clinical features (Table 5, available at http://aaojournal.org). Survival 331 
curves for age to first onset of symptoms suggested those with the p.Met66Arg mutation or deletions had 332 
an earlier onset of symptoms (median age of onset 30 years for both groups) compared to those with other 333 
substitutions (median age 41 years), although these differences did not reach statistical significance (p log 334 
rank=0.17, Table 5, available at http://aaojournal.org, Figure 9A). Combining the present data with 335 
published results from Lai et al.15 (12 patients heterozygous or homozygous for deletions, 6 heterozygous 336 
or homozygous for other substitutions) strengthened the impression of earlier onset of symptoms for 337 
p.Met66Arg homozygotes (Figure 9B), and the log rank test reached statistical significance (p=0.03). Mean 338 
visual acuity was worse for patients with deletions (6/60) compared to those with p.Met66Arg (6/18) or 339 
other substitutions (6/15) in the present cohort but these differences did not reach statistical significance. 340 
Including patients from Lai et al.15 and adjusting for age and gender reinforced these impressions but the 341 
differences remained non-significant (p>0.05, data not shown). The analyses were repeated for visual 342 
acuity in the better, and in the worse seeing eye, with similar results. All (4/4, 100%) patients with deletion 343 
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of exon 7 had stage 3 disease compared with 5/11 (45%) for those with p.Met66Arg and 3/5 (60%) for 344 
those with other substitutions. Similarly, all (3/3, 100%) with deletions had severe generalized full field ERG 345 
abnormalities compared with 2/5 (40%) patients with p.Met66Arg and none with other substitutions. These 346 
differences did not reach statistical significance both before and after adjustment for age and gender. 347 
Discussion 348 
To date, most patients with BCD that have been reported are of East Asian descent3, 5, 15-25 where the 349 
prevalence of BCD seems to be higher.26 The present study of British multi-ethnic patients shows significant 350 
variability in both phenotypic presentation and severity of disease consistent with prior reports in Asian 351 
cohorts and suggests other gene and environmental interactions.4, 5, 7-9 352 
Few previous studies to date have utilized FAF imaging in BCD.4, 5, 8 The present study found that areas of 353 
uninvolved peripheral retina on color images correspond to areas of normal FAF, while areas of involved 354 
retina start out as areas of abnormal FAF and progress to become sharply demarcated areas of hypo-AF. 355 
These hypo-AF areas represent areas of RPE cell loss and their well defined edges correspond to areas of 356 
abrupt outer retinal atrophy on SD-OCT. Similar SD-OCT appearances occur in other diseases with a 357 
postulated primary RPE pathology such as gyrate atrophy and choroideremia.27 The lack of AF associated 358 
with the crystals themselves is consistent with suggestions that the crystals in BCD may represent 359 
collections of cholesterol esters from abnormal lipid metabolism,28 although the precise composition of the 360 
crystals remains unclear.29 361 
There has been controversy as to the location within the retina of the crystalline deposits in BCD. Some 362 
report hyperreflective spots on the RPE/Bruch’s membrane complex on SD-OCT,4 while others have 363 
reported similar looking hyperreflective spots throughout the neurosensory retina and choroid6, 8, 9 which 364 
has been interpreted as crystal deposition occurring throughout the retina and choroid. Using SD-OCT with 365 
co-registration of lesions to NIR images, the vast majority of crystals in the present series were either on or 366 
in the RPE/Bruch’s membrane complex with a small number of crystals located elsewhere in the retina. 367 
There were none in the choroid. Many hyperreflective spots on SD-OCT did not correspond to crystals or 368 
any other visible abnormality on either NIR or color images; these may be related to clusters of 369 
inflammatory cells, a gliotic response to retinal degeneration33 protein deposits or simply artefacts. In 370 
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patient 19 it is clear that the crystals are an early manifestation of the disorder, and need not be 371 
accompanied by altered retinal function.6 372 
The evolution of crystals documented using serial SD-OCT imaging showed that in the early stages crystals 373 
appear in the RPE/Bruch’s membrane complex with preservation of the overlying external limiting 374 
membrane. Atrophy and thinning of the RPE/Bruch’s membrane complex was associated with 375 
disappearance of the crystals, as well as loss of the photoreceptor ellipsoid and external limiting membrane 376 
layers and formation of outer retinal tubulations. These findings are consistent with the clinical 377 
observations that despite the presence of numerous crystals there can be relatively preserved visual acuity 378 
(cases 10 and 17) or normal macular function (patient 19),while the loss of crystals over time is associated 379 
with expanding RPE and inner choroidal atrophy and loss of macular function (patients 1, 3, 7). It can be 380 
speculated that crystals may be a visible phenotype of metabolic dysfunction in RPE or photoreceptor cells 381 
and their disappearance associated with cell death. It has not been possible to determine if crystals are 382 
intra- or extracellular deposits, although histopathological studies report the presence of crystalline 383 
intracellular inclusions in extraretinal lymphocytes and fibroblasts in patients with BCD.28, 29 Tubulations, 384 
believed to be photoreceptor rosettes, have previously been reported in BCD, as well as multiple other 385 
conditions, including age-related macular degeneration, pseudoxanthoma elasticum and gyrate atrophy30, 31 386 
and suggests that the site of initial dysfunction is likely to be the RPE, with photoreceptor degeneration a 387 
secondary consequence. 388 
Delayed and subnormal ERGs consistent with generalized rod and cone dysfunction were present in all 389 
cases with extensive RPE and choroidal atrophy (Table 2, available at http://aaojournal.org). Mildly reduced 390 
rod- and/or cone-mediated ERGs without delay suggest restricted loss of retinal function and occurred in 391 
those with focal areas of macular atrophy. Other patients showed no full-field ERG abnormality. Previous 392 
studies report full-field ERGs ranging from normal to undetectable, with most having generalized rod and 393 
cone system involvement.5, 15, 28, 32-34 Serial ERG data are not available for the present cohort, but 394 
progressive ERG worsening has been documented by others.32, 33 Multifocal ERG reduction and delay have 395 
also been reported in keeping with macular dysfunction5, 15 and it is of interest that a high proportion of the 396 
present series showed significant PERG P50 delay, with or without amplitude reduction; in general, delays 397 
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in P50 occur less frequently in genetically determined macular dysfunction than amplitude reduction, and 398 
rarely occur unaccompanied by amplitude reduction. 399 
Eleven sequence variants were identified, 7 of which are novel and the majority of which are missense 400 
mutations (accounting for 74% of chromosomes in this cohort), in contrast to previous observations 401 
indicating the most common variant is the deletion c.802-8_810del17insGC.24, 35 A review of the literature 402 
by Xiao et al. shows that this deletion accounts for 63% of the mutated alleles reported to date in patients 403 
of Chinese or Japanese origin.24 The most common mutation (16/34 alleles) in the present cohort was a 404 
novel missense mutation p.Met66Arg. This was identified in the homozygous state in all 8 families of South 405 
Asian descent, suggesting that exon 1 should be screened first in such patients; just as patients of East 406 
Asian descent should have exon 7 screened first to exclude the indel c.802-8_810del17insGC. Interestingly, 407 
this novel substitution appeared to be associated with an earlier onset of symptoms. This finding should be 408 
interpreted with caution as it may be related to biases such as recall bias (i.e. the two sons in family 409 
GC19455 with an affected parent may be more aware of symptoms and hence report earlier onset) and 410 
issues with pooling data from another centre in a different country and health system15 Nonetheless, this 411 
substitution still appears to be related to earlier onset of symptoms even after excluding data from family 412 
GC19455 and Lai et al.15 The specific amino acid sequence and surrounding region is highly conserved in 413 
mammals but not in non-mammalian animals or invertebrates.  414 
In terms of clinical severity, patients with deletions seemed to have more severe disease and worse visual 415 
acuity. The 17bp deletion (c.802-8_810del17insGC) includes the exon 7 splice acceptor site and so causes 416 
an in-frame deletion of exon 7 that would result in expression of a truncated 463 amino acid protein.3 This 417 
deletion has previously been reported to be associated with a more severe ERG phenotype.15 418 
Since 2004 there have been 20 reports, including this one, documenting over 50 different mutations in 419 
CYP4V2.3, 5, 6, 8, 15, 36-39 The missense and nonsense mutations reported to date are summarized in Figure 6, 420 
available at http://aaojournal.org. CYP4V2 is an 11 exon gene encoding a predicted protein of 525 amino 421 
acids, with mutations identified across the entire gene (Figure 6, available at http://aaojournal.org). A 422 
recent study by Nakano and colleagues reported p.H331P as the most common missense mutation, 423 
accounting for 7% of all mutated alleles, compared to the 63% of alleles with the c.802-8_810del17insGC 424 
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deletion.40 They went on to demonstrate that the p.H331P mutant encodes an unstable protein. This is the 425 
only report showing that a change in CYP4V2 results in a non-functional protein. Further studies need to be 426 
undertaken to determine the effect of the other described missense and nonsense mutations on the 427 
function of CYP4V2.  428 
A number of biochemical findings indicate systemic abnormalities of lipid metabolism in patients with 429 
BCD.41, 42 CYP4V2 is the most distinct of the human CYP4 family with only ~35% sequence identity to other 430 
family members.43 The encoded protein is a microsomal omega (ω)-hydroxylase that functions together 431 
with mitochondrial and peroxisomal β-oxidation enzymes to degrade cellular lipids, with a preference forω-432 
3 polyunsaturated fatty acids (PUFA)s such as docosahexaenoic acid (DHA) and eicosapentaenoic acid 433 
(EPA).44 These PUFAs are important constituents of photoreceptor outer segments that are recycled by RPE 434 
cells. In addition to being structural components, some PUFA derived metabolites e.g. resolvin and 435 
protectin possess anti-inflammatory and immunoregulatory signaling properties which may be disrupted by 436 
mutations in CYP4V2.43 The protein is expressed in human RPE, retina, cornea and many other tissues 437 
including kidney, liver, lung and lymphocytes.3, 40 Its phenotypic effects may be most prominent in the RPE 438 
where it appears to be the primary CYP4 protein expressed.40 Together with the presented imaging data, 439 
such evidence further implicates the RPE as the cellular site of dysfunction in BCD. Given that the 440 
therapeutic window from onset of symptoms to severe vision loss is a decade or more, this offers the 441 
possibility of pharmacologic intervention to delay progression. 442 
This study was not prospective and although all available data are presented for all patients, it is inevitable 443 
that patients seen earlier before the introduction of new imaging modalities did not have these performed. 444 
Six patients had complete imaging and ERG assessment. It is possible that this may have introduced a bias 445 
but we believe this is unlikely as the six patients with complete assessments are a representative sample 446 
that spans a large age range (15-40 years at time of ERGs) and the full spectrum of severity on both ERG 447 
and clinical severity 448 
In conclusion, this report expands and refines the phenotypic characteristics of Bietti Crystalline Dystrophy. 449 
FAF showed sharply demarcated areas of RPE loss which coincided with abrupt edges of outer retinal 450 
atrophy on SD-OCT. The crystals, which are best visualized using NIR imaging and which are not evident on 451 
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FAF imaging, are shown by SD-OCT to be located on or in the RPE/Bruch’s membrane complex; this 452 
combined with other data suggests that RPE dysfunction underlies disease pathogenesis. The mutation 453 
spectrum in this multi-ethnic British cohort, including novel mutations, differs to that previously described 454 
in other populations.  455 
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Table 3. In silico analysis of missense mutations in CYP4V2 
 









NN output Reliability Prediction References 
1 c.77G>A, p.Gly26Asp   Tolerated 0.21  PRD 0.989  0.3834 2 Neutral Novel to this study 
1 c.197T>G p.Met66Arg  Intolerant 0.02  Benign 0.009  0.8042 6 Pathological Novel to this study 
2 c.283G>A, p.Gly95Arg   Intolerant 0.01  PRD 1.000  0.8878 7 Pathological 6, 23 
6 c.677T>A, Met226Lys  Intolerant 0.00  PRD 0.989  0.6214 2 Pathological Novel to this study 
8 c.998C>A, p.Thr333Lys   Intolerant 0.00  PRD 1.000  0.8480 6 Pathological Novel to this study 
9 c.1503G>A, p.Arg400His  Intolerant 0.00  PRD 1.000  0.5805 1 Pathological 18, 23, 27 
10 c.1393A>G, p.Arg465Gly  Intolerant 0.00  PRD 1.000  0.6607 3 Pathological 8 
 
SIFT15 results are reported to be tolerant if tolerance index ≥0.05 or intolerant if tolerance index <0.05 
Polyphen 216 appraises mutations qualitatively as Benign, PossiblyDamaging (POS) or Probably damaging (PRD) based on the model's false positive rate 
pMUT17 is based on the use of different kinds of sequence information to label mutations, and neural networks to process this information NN=neural network values 
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Table 4. SNPs identified in CYP4V2 
 
rs number  Exon/intron Nucleotide  Amino acid dbSNP MAF  
(minor allele frequency) 
rs1055138 Exon 1 c.64C>G 
 
p.Leu22Val G=0.4390 
rs10013653 Intron 1 c.215-22C→A 
 
 A=0.4222 
rs7682918 Intron 2 c.327+75C→T 
 
 T=0.3201 





rs4862662 Intron 4 c.605-25G→T 
 
 T=0.3512 
rs13146272 Exon 6 c.775C>A 
 
p.Gln259Lys C=0.4547 
rs3817184 Intron 6 c.802-7C→T 
 
 0.424 
rs34745240 Exon 7 c.823G>A 
 
p.Glu275Lys A=0.0298 
rs3736455 Exon 7 c.810T>G 
 
p.Ala270Ala T=0.4492 
rs3216724 Intron 8 c.1090+99delC 
 
 -=0.326 
rs2276918 Intron 9 IVS9+45A→G 
 
 G=0.3365 
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Figure 2. Color imaging, fundus autofluorescence (AF) and Spectral domain Optical Coherence 
Tomography (SD-OCT) imaging.  
Color, AF and SD-OCT scanning of patients with different presentations, patient 13 panels A-C; 
patient 14 panels D-F; patient 15 panels G-I; patient 8 panels J-L and patient 11 panels M-O. Panels 
A-C from patient 13 show localized disease confined to the macula. Areas of normal looking retina 
on color images (A) show normal AF (B). Affected areas (B) show disrupted outer retinal layers on 
SD-OCT (C). Panels D-F from patient 14 (younger brother of patient 13) show more severe disease 
with more widespread abnormalities on AF (E). The sharp transition from abnormal AF to hypo-AF 
(E) corresponds on OCT (F) to a fairly abrupt transition from relatively intact retinal layers to loss of 
outer retinal layers including the outer plexiform and nuclear layers (up arrow). Panels G-O show 
patients with more severe, generalized disease and low AF suggesting widespread loss of retinal 
pigment epithelium (RPE). In patient 8, the central island of relatively preserved retina (J) on AF (K) 
corresponds to relatively preserved outer retinal layers on OCT (L) and highlights again the sharp 
demarcation (up arrows) between this preserved island and the surrounding hypo-AF retina (K) and 
atrophic outer retinal layers (L). Patient 11 (M) illustrates the usefulness of AF in demonstrating the 
clearly defined areas of RPE loss with a small island of preserved central retina (N), that is also visible 
on SD-OCT (O). 
 
Figure 3. Color photographs of crystals and corresponding appearances on autofluorescence (AF), 
near infra-red and spectral domain optical coherence tomography (SD-OCT).  
Patient 14 panels A-D; patient 19 panels E-H. Color photograph showing crystals (A, arrows, 
arrowheads, patient 14). Crystals are neither hyper nor hypo-AF (B) but show up clearly on near 
infra-red imaging (C). SD-OCT shows that the crystals are located in or on the retinal pigment 
epithelium/Bruch’s membrane layer (D, arrow). A similar appearance is shown for crystals in a 




plexiform layer on SD-OCT (H, down arrow) does not correspond to a crystal on either color 
photography, AF or near infra-red (E-G).  
 
Figure 4. Longitudinal evolution of crystals over 2-3 years. 
Comparative scans from Patient 11 are shown from 2010 and 2012 (A-H) and from patient 10 from 
2009 and 2012 (I-L). Panels A-D show the appearance of a new crystal in the retinal pigment 
epithelium (RPE) /Bruch’s membrane layer in 2012 (C, D arrows), which was not present in 2010 (A, 
B patient 11). Panels E and F from the same patient in 2010 show a crystal in the RPE/Bruch’s 
membrane complex with a granular appearance to the overlying ellipsoid line and external limiting 
membrane. Between 2010 and 2012, this crystal disappeared on both near infra-red and Spectral 
domain Optical Coherence Tomography (SD-OCT) scanning, with disruption and loss of the 
RPE/Bruch’s membrane and overlying ellipsoid (photoreceptor) and external limiting membrane 
(G,H). Figures I-L compare images obtained in 2009 with those obtained in 2012 for patient 10. In 
panel I there is a crystal at the margin of an atrophic zone, which on SD-OCT imaging (J) has a 
present ellipsoid line and to a lesser extent, external limiting membrane line. Over 3 years, the area 
of atrophy expanded (K) with disappearance of the crystal on near infra-red and appearance of a 
new crystal (black arrow, K). The disappearance of the crystal corresponds to thinning of the 
RPE/Bruch’s membrane layer, loss of ellipsoid and external limiting membrane lines, and the 
formation of possible early tubulation (L).  
 
Figure 9. Kaplan Meier survival curves for survival time to first onset of symptoms by mutation type. 
Panel A includes patients from this study; Panel B also incorporates data from Lai et al.15 Patients 
with p.Met66Arg mutations had earlier onset of symptoms than those with other substitutions (p 
logrank=0.03). Patient 12 was excluded from analyses due to uncertain age of onset of symptoms 
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